Infographics

How a Biologics CDMO Adds Value to mAbs Development & Manufacturing Programs

A look at a CDMO’s value throughout a monoclonal antibody (mAb) therapeutic's lifecycle.

Company Logo

Released By Scorpius BioManufacturing

The growing number of monoclonal antibodies (mAbs), and the maturation of their process development and manufacturing, have led to contract development and manufacturing organizations (CDMOs) playing an increasingly important role in expediting these programs’ path to commercialization. This infographic explores how an experienced biologics CDMO adds value throughout a mAb’s lifecycle.



 

Request more information from Scorpius BioManufacturing

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters